PPARγ (Peroxisome Proliferator-Activated Receptor γ) Deacetylation Suppresses Aging-Associated Atherosclerosis and Hypercholesterolemia

被引:9
|
作者
Zahr, Tarik [1 ,2 ]
Liu, Longhua [1 ,3 ]
Chan, Michelle [1 ]
Zhou, Qiuzhong [5 ]
Cai, Bishuang [6 ]
He, Ying [1 ,3 ]
Aaron, Nicole [1 ,2 ]
Accili, Domenico [1 ,4 ]
Sun, Lei [5 ]
Qiang, Li [1 ,3 ,7 ]
机构
[1] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY USA
[2] Columbia Univ, Dept Mol Pharmacol & Therapeut, New York, NY USA
[3] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA
[4] Columbia Univ, Dept Med, New York, NY USA
[5] Duke NUS Med Sch, Cardiovasc & Metab Disorders Program, Singapore, Singapore
[6] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY USA
[7] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10032 USA
基金
美国国家卫生研究院;
关键词
aging; atherosclerosis; cardiovascular disease; hypercholesterolemia; inflammation; FATTY LIVER-DISEASE; GENE-EXPRESSION; PROMOTES ATHEROSCLEROSIS; LIPID-METABOLISM; ADIPOSE-TISSUE; BLOOD-PRESSURE; INFLAMMATION; MACROPHAGES; CHOLESTEROL; THIAZOLIDINEDIONES;
D O I
10.1161/ATVBAHA.122.318061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:Atherosclerosis is a medical urgency manifesting at the onset of hypercholesterolemia and is associated with aging. Activation of PPAR gamma (peroxisome proliferator-activated receptor gamma) counteracts metabolic dysfunction influenced by aging, and its deacetylation displays an atheroprotective property. Despite the marked increase of PPAR gamma acetylation during aging, it is unknown whether PPAR gamma acetylation is a pathogenic contributor to aging-associated atherosclerosis. Methods:Mice with constitutive deacetylation-mimetic PPAR gamma mutations on lysine residues K268 and K293 (2KR) in an LDL (low-density lipoprotein)-receptor knockout (Ldlr(-/-)) background (2KR:Ldlr(-/-)) were aged for 18 months on a standard laboratory diet to examine the cardiometabolic phenotype, which was confirmed in Western-type diet-fed 2KR:Ldlr(+/-) mice. Whole-liver RNA-sequencing and in vitro studies in bone marrow-derived macrophages were conducted to decipher the mechanism. Results:In contrast to severe atherosclerosis in WT:Ldlr(-/-) mice, aged 2KR:Ldlr(-/-) mice developed little to no plaque, which was underlain by a significantly improved plasma lipid profile, with particular reductions in circulating LDL. The protection from hypercholesterolemia was recapitulated in Western-type diet-fed 2KR:Ldlr(+/-) mice. Liver RNA-sequencing analysis revealed suppression of liver inflammation rather than changes in cholesterol metabolism. This anti-inflammatory effect of 2KR was attributed to polarized M2 activation of macrophages. Additionally, the upregulation of core circadian component Bmal1 (brain and muscle ARNT-like 1), perceived to be involved in anti-inflammatory immunity, was observed in the liver and bone marrow-derived macrophages. Conclusions:PPAR gamma deacetylation in mice prevents the development of aging-associated atherosclerosis and hypercholesterolemia, in association with the anti-inflammatory phenotype of 2KR macrophages.
引用
收藏
页码:30 / 44
页数:15
相关论文
共 50 条
  • [41] Peroxisome proliferator-activated receptor gamma (PPARγ) activation and its consequences in humans
    Bar-Tana, J
    TOXICOLOGY LETTERS, 2001, 120 (1-3) : 9 - 19
  • [42] Ligands and Regulatory Modes of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Avians
    Navidshad, B.
    Royan, M.
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2015, 25 (04): : 287 - 292
  • [43] Macrophage immunophenotype but not anti-inflammatory profile is modulated by peroxisome proliferator-activated receptor gamma (PPARγ) in exercised obese mice
    Silveira, Loreana Sanches
    Biondo, Luana Amorim
    de Souza Teixeira, Alexandre Abilio
    de Lima Junior, Edson Alves
    Castoldi, Angela
    Saraiva Camara, Niels Olsen
    Festuccia, Willian T.
    Rosa-Neto, Jose Cesar
    Lira, Fabio Santos
    EXERCISE IMMUNOLOGY REVIEW, 2020, 26 : 94 - 106
  • [44] Expression of peroxisome proliferator-activated receptor subtypes in human atherosclerosis
    Sueyoshi, S
    Yamada, T
    Niihasi, M
    Kusumi, Y
    Oinuma, T
    Esumi, M
    Tsuru, K
    Imai, S
    Nemoto, N
    Sakura, I
    Mitsumata, M
    ATHEROSCLEROSIS VI, 2001, 947 : 429 - 432
  • [45] Modulation of Peroxisome Proliferator-Activated Receptor gamma (PPAR γ) by Conjugated Fatty Acid in Obesity and Inflammatory Bowel Disease
    Yuan, Gaofeng
    Chen, Xiaoe
    Li, Duo
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2015, 63 (07) : 1883 - 1895
  • [46] Peroxisome proliferator-activated receptor γ:: Implications for cardiovascular disease
    Hsueh, WA
    Bruemmer, D
    HYPERTENSION, 2004, 43 (02) : 297 - 305
  • [47] Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease
    Fruchart, Jean-Charles
    ATHEROSCLEROSIS, 2009, 205 (01) : 1 - 8
  • [48] Imaging and peroxisome proliferator-activated receptor agonists: Uncovering their role in atherosclerosis development
    Nissen, SE
    CLINICAL CARDIOLOGY, 2004, 27 (07) : 17 - 20
  • [49] The peroxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function
    Ricote, M
    Huang, JT
    Welch, JS
    Glass, CK
    JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 66 (05) : 733 - 739
  • [50] Peroxisome proliferator-activated receptor (PPAR) isoforms in coronary heart disease
    Aydogan, Hulya Yilmaz
    Kurt, Ozlem
    Kurnaz, Ozlem
    Teker, Basak Akadam
    Kucukhuseyin, Ozlem
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2013, 38 (04): : 372 - 384